Daiwa: WUXI XDC proposes to fully acquire Dongyao Pharmaceutical and gives WuXi Biologics a "Buy" rating

Daiwa published a research report stating that WuXi Biologics (02269.HK) and WUXI XDC (02268.HK) announced a comprehensive acquisition offer at a maximum cost of approximately HKD 2.8 billion to acquire at least 60% of the shares of Voyah (01875.HK), and it is expected that Voyah will maintain its listing status after the completion.

WUXI XDC anticipates that this acquisition will help expand its business and gain additional operational production capacity in China, further enriching its project portfolio and expanding its customer base, thereby consolidating its leading market position in the field of ADC contract research and manufacturing organizations. Daiwa currently gives WuXi Biologics (02269.HK) an investment rating of "Buy."